SCHEMBL5542866

SCHEMBL5542866

FC(F)(F)Oc1ccc(O[CH]c2ccccc2)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.42
PPARA Q07869 5/20 0.38
PPARD Q03181 3/20 0.38
GPR3 P46089 2/20 0.37
KIF11 P52732 1/20 0.37
FFAR4 Q5NUL3 3/20 0.37
FFAR1 O14842 2/20 0.37
CYP2C9 P11712 1/20 0.36
SCN5A Q14524 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
PNLIP P16233 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
CTSC P53634 2/20 0.35
CHRM5 P08912 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092357 0.78 MRGPRX4 (0.45) MRGPRX4PPARAPPARDGPR3FFAR4
SCHEMBL10825618 0.77 MRGPRX4 (0.48) MRGPRX4PPARAPPARDGPR3FFAR4
SCHEMBL5545196 0.76 PIM1 (0.38) GPR3KIF11SCN5APIM1PIM2
SCHEMBL5544083 0.74 CYP1A1 (0.44)
SCHEMBL1047193 0.73 MRGPRX4 (0.45) MRGPRX4PPARAPPARDGPR3KIF11
SCHEMBL1047194 0.73 MRGPRX4 (0.45) MRGPRX4PPARAPPARDGPR3FFAR4
SCHEMBL24512667 0.72 SCN3A (0.49) MRGPRX4PPARAPPARDCYP2C9PNLIP
SCHEMBL6090020 0.71 MRGPRX4 (0.44) MRGPRX4PPARAPPARDGPR3KIF11
SCHEMBL8698936 0.71 PPARG (0.41) MRGPRX4PPARATDP1PPARG
SCHEMBL28565710 0.71 PNLIP (0.46) MRGPRX4PNLIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MRGPRX4 3620/4885PPARA 429/4885PPARD 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.